Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Recent News

Early Results of Phase I Study of CAR T-Cell Therapy in Multiple Myeloma
Novel Four-Drug Combination Therapy for Newly Diagnosed Multiple Myeloma
First-in-Class Agent Targets NF-kB Signaling in Multiple Myeloma
Venetoclax Combination Therapy for Resistant Multiple Myeloma
ASH 2018: First-Line Combination Regimens in Transplant-Ineligible Patients With Myeloma
ASH 2018: Novel Agent for Resistant Multiple Myeloma Under Study
ASH 2018: Is Urine Immunofixation Necessary to Define Complete Remission in Myeloma
ASH 2018: Frailty-Adjusted Treatment Approach for Elderly Patients With Myeloma
ASH 2018: Ixazomib Maintenance After Transplantation in Newly Diagnosed Multiple Myeloma
ASH 2018: Double vs. Single Autologous Transplantation in Newly Diagnosed Myeloma
ASH 2018: Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma
ASH 2018: Transplant Versus Continuous Lenalidomide-Based Therapy for Relapsed Multiple Myeloma
Myeloma Crowd Launches Free Online Resource for Patients With Multiple Myeloma
FDA Grants Regenerative Medicine Advanced Therapy Designation to CAR T-Cell Therapy
ESMO 2018: Adding Liposomal Doxorubicin to Standard First-Line Therapy in Multiple Myeloma
FDA Grants Priority Review to Ruxolitinib for Acute Graft-Versus-Host-Disease
ASTRO 2018: Impact of Dosage on Re-irradiation Rates in Multiple Myeloma
FDA Approves Immunotherapy Combination in Relapsed or Refractory Multiple Myeloma
Rare Case of CML After Stem Cell Transplantation in Patient With Multiple Myeloma
Phase I Study of New Triplet Therapy for Resistant Myeloma
FDA Offers Draft Guidance on Use of MRD in Hematologic Malignancies
Investigational Therapy for Myeloma, STRO-001, Granted Orphan Drug Designation by FDA
ESMO 2018: Strategy for Offsetting Lenalidomide-Induced Rash in Multiple Myeloma
FDA Grants Priority Review to Selinexor for Pentarefractory Multiple Myeloma
Can Simple Blood Tests Diagnose Early Multiple Myeloma?
FDA Permits Use of Next-Generation Sequencing–Based Test in Multiple Myeloma
Quality Care Symposium: Steady Improvement in Survival in Multiple Myeloma
FDA Approves Once-Weekly Carfilzomib With Dexamethasone in Resistant Multiple Myeloma
Novel Approach to Restoring Beneficial Gut Bacteria After HCT
Can Artificial Intelligence Platform Optimize Combination Therapy for Multiple Myeloma?
High-Risk Subset of Newly Diagnosed Multiple Myeloma Identified
Is Resilience a Protective Factor in Disease Trajectory of Multiple Myeloma?
Former MLB Sluggers Team up to Create Awareness of Multiple Myeloma
Monoclonal Antibodies in Multiple Myeloma: Focus on Infusion-Related Reactions
ALL After Multiple Myeloma: Clonally Related or Not?
FDA Accepts Supplemental Biologics License Application for Triplet Myeloma Therapy
Accuracy of Blood Versus Urine Assays in Diagnosis of Multiple Myeloma
Potential of bb2121 CAR T-Cell Therapy in Resistant Multiple Myeloma
UAB Leads Recruitment for Novel Clinical Trial in Multiple Myeloma
Phase III ADMYRE Trial: Plitidepsin + Dexamethasone in Resistant Myeloma
FDA Issues Warning About Long-Term Use of Azithromycin After Donor Stem Cell Transplant
Pembrolizumab in Combination Therapy for Resistant Multiple Myeloma
FDA Grants Orphan Drug Designation to Human Antibody for Treatment of Multiple Myeloma
FDA Grants Fast Track Designation to Galinpepimut-S for Treatment of Myeloma
Preliminary Safety Results of Triplet Therapy for Multiple Myeloma Reported


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.